To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: AUA MEETING: Uprima Shows Promise In Patients With Erectile Dysfunction URL: http://www.pslgroup.com/dg/FBCEA.htm Doctor's Guide May 5, 1999
DEERFIELD, IL -- May 5, 1999 -- Data from three Phase III studies presented yesterday at the American Urological Association meeting in Dallas, TX., suggest that TAP Pharmaceuticals' dopamine receptor agonist, Uprima(TM) (apomorphine HCL tablets) sublingual, can increase the number of successful intercourse attempts. Uprima is a central initiator that works by stimulating an erection through mechanisms originating in the brain. "The results of this study are promising and provide hope for the approximately 30 million Americans who suffer from some form of erectile dysfunction," said Harin Padma-Nathan, M.D., director, The Male Clinic, Beverly Hills, CA., and an investigator in the studies. Erectile dysfunction is defined as the inability to obtain and maintain an erection sufficient for intercourse. The three studies were multicentre, double-blind studies where patients were randomised to four treatment arms of Uprima versus placebo -- 2 mg, 4 mg, 5 mg and 6 mg. The studies measured the number of attempts resulting in an erection firm enough for intercourse. The first presentation consisted of data from a study that evaluated 520 male erectile dysfunction patients and found that the Uprima doses demonstrated a significantly higher percentage of attempts resulting in an erection firm enough for intercourse versus placebo (2 mg group -- 44 percent versus 38 percent; 4 mg group -- 58 percent versus 37 percent; 5 mg group -- 53 percent versus 29 percent and 6 mg group - 61 percent versus 29 percent; respectively). The second presentation consisted of data from two studies and found similar results in hypertension patients. Hypertension is associated with erectile dysfunction. The study evaluated 977 patients, of which 236 were hypertensive and found that the Uprima doses also demonstrated a significantly higher percentage of attempts resulting in an erection firm enough for intercourse versus placebo (2 mg group -- 42 percent versus 32 percent; 4 mg group -- 51 percent versus 28 percent; 5 mg group -- 46 percent versus 30 percent; and 6 mg group -- 63 percent versus 33 percent; respectively). The most common adverse event reported in these studies was nausea, mostly mild-to-moderate. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.